SLC5A2 and heart failure: Meanwhile, the cardiovascular field has introduced new anticoagulants (e.g., DOACs), PCSK9 inhibitors, and SGLT2 inhibitors, alongside updated guidelines for hypertension and heart failure, such as stricter blood pressure targets and recommendations for novel therapies.